- The USPTO has issued a new patent, No. 10,213,390, to Zynerba Pharmaceuticals (NASDAQ:ZYNE) covering the use of its cannabidiol transdermal gel (ZYN002) to treat Fragile X syndrome, an inherited disorder characterized by learning disabilities and cognitive impairment. Shares are up 17% premarket on increased volume.
Zynerba up 17% premarket on new cannabidiol gel patent
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ZYNE | - | - |
Zynerba Pharmaceuticals, Inc. |